Last reviewed · How we verify
sorafenib, TS-1
At a glance
| Generic name | sorafenib, TS-1 |
|---|---|
| Sponsor | Samsung Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Sorafenib Plus S-1 in Advanced Solid Tumors (PHASE1)
- Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sorafenib, TS-1 CI brief — competitive landscape report
- sorafenib, TS-1 updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI